UNLABELLED: This study examined perceived risks, benefits, and desired information related to willingness to volunteer in preventive HIV vaccine trials. SAMPLE: Purposive sampling was used to select 90 participants among injecting drug users (Philadelphia, PA, U.S.A.); gay men (San Francisco, CA, U.S.A.); and black Americans (Durham, NC, U.S.A.). METHODS: A qualitative interview guide elicited perceived benefits, risks, and desired information relating to trial participation. Themes were developed from the transcribed texts and from freelists. RESULTS: Stated willingness to volunteer in a preventive HIV vaccine trial was similar across the three communities. Eight perceived benefits were reported, including self-benefits, altruism, and stopping the spread of AIDS. Seven perceived risks were reported, including negative side effects and vaccine safety issues, contracting HIV from the vaccine, and social stigmatization. Participants voiced the desire for eight types of information about issues relating to trust and confidentiality in the research process, health complications and later assistance, and vaccine trial methodology. CONCLUSIONS: In this study, many benefits as well as risks of preventive HIV vaccine trial participation were cited. Scientists conducting preventive HIV vaccine trials need to address community perceptions of risks and provide information about the research if trial enrollment is to be diverse and successful.
UNLABELLED: This study examined perceived risks, benefits, and desired information related to willingness to volunteer in preventive HIV vaccine trials. SAMPLE: Purposive sampling was used to select 90 participants among injecting drug users (Philadelphia, PA, U.S.A.); gay men (San Francisco, CA, U.S.A.); and black Americans (Durham, NC, U.S.A.). METHODS: A qualitative interview guide elicited perceived benefits, risks, and desired information relating to trial participation. Themes were developed from the transcribed texts and from freelists. RESULTS: Stated willingness to volunteer in a preventive HIV vaccine trial was similar across the three communities. Eight perceived benefits were reported, including self-benefits, altruism, and stopping the spread of AIDS. Seven perceived risks were reported, including negative side effects and vaccine safety issues, contracting HIV from the vaccine, and social stigmatization. Participants voiced the desire for eight types of information about issues relating to trust and confidentiality in the research process, health complications and later assistance, and vaccine trial methodology. CONCLUSIONS: In this study, many benefits as well as risks of preventive HIV vaccine trial participation were cited. Scientists conducting preventive HIV vaccine trials need to address community perceptions of risks and provide information about the research if trial enrollment is to be diverse and successful.
Authors: Edith A M Tarimo; Anna Thorson; Thecla W Kohi; Joachim Mwami; Muhammad Bakari; Eric Sandström; Asli Kulane Journal: BMC Public Health Date: 2010-05-28 Impact factor: 3.295
Authors: Rebecca Giguere; Gregory D Zimet; Jessica A Kahn; Curtis Dolezal; Cheng-Shiun Leu; Marina Mabragaña; Ian McGowan; Alex Carballo-Diéguez Journal: World J AIDS Date: 2013-09
Authors: Michele Peake Andrasik; Christian Chandler; Borris Powell; Damon Humes; Steven Wakefield; Katharine Kripke; Daniel Eckstein Journal: Am J Public Health Date: 2014-02-13 Impact factor: 9.308
Authors: Paula M Frew; Matthew Archibald; Dazon Dixon Diallo; Su-I Hou; Takeia Horton; Kayshin Chan; Mark J Mulligan; Carlos del Rio Journal: Prev Sci Date: 2010-06
Authors: Barbara S Mensch; Barbara A Friedland; Sharon A Abbott; Lauren L Katzen; Waimar Tun; Christine A Kelly; Avina Sarna; Aylur K Srikrishnan; Suniti Solomon Journal: AIDS Behav Date: 2013-02